On 14 February 2001, orphan designation (EU/3/01/022) was granted by the European Commission to Genzyme BV, the Netherlands, for Laronidase for the treatment of mucopolysaccharidosis, type I.
The sponsor changed name to Genzyme Europe BV in 2002.
Laronidase has been authorised in the EU as Aldurazyme since 10 June 2003.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
|Disease / condition||
Treatment of mucopolysaccharidosis type I
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.